Instil Bio Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| INSTIL BIO, INC. | ||
| March 21, 2024 | By: | /s/ Bronson Crouch |
|---|---|---|
| Bronson CrouchChief Executive Officer | ||
Signatures And Power of Attorney
Know all persons by these presents, that each person whose signature appears below constitutes and appoints Bronson Crouch and Sandeep Laumas, M.D., jointly and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:
| Signature | Title | Date |
|---|---|---|
| /s/ Bronson Crouch | Chief Executive Officer and Chairman | March 21, 2024 |
| Bronson Crouch | (Principal Executive Officer) | |
| /s/ Sandeep Laumas, M.D. | Chief Financial Officer and Chief Business Officer | March 21, 2024 |
| Sandeep Laumas, M.D. | (Principal Financial and Accounting Officer) | |
| /s/ Gwendolyn Binder, Ph.D. | Director | March 21, 2024 |
| Gwendolyn Binder, Ph.D. | ||
| /s/ Neil Gibson, Ph.D. | Director | March 21, 2024 |
| Neil Gibson, Ph.D. | ||
| /s/ George Matcham, Ph.D. | Director | March 21, 2024 |
| George Matcham, Ph.D. | ||
| /s/ R. Kent McGaughy, Jr. | Director | March 21, 2024 |
| R. Kent McGaughy, Jr. | ||
| /s/ Jack Nielsen | Director | March 21, 2024 |
| Jack Nielsen | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.